Company intelligence / Profile preview

GIO Therapeutics

Basel, Basel-Stadt, Switzerlandgiotherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

GIO Therapeutics is a newly established biotech company focused on developing small molecule drugs that target GPCRs for the treatment of cancer and inflammatory diseases. The company’s lead program targets GPR68 and is currently in preclinical development. No clinical results have been reported yet.

Therapeutic areas: OncologyImmunology
Modalities: Small molecules (targeting GPCRs)
Industry: Biotech

Partnerships

leadXpro AG (structure-based drug discovery partner for membrane proteins including GPCRs; partnered on the GPR68 project)

Beyond the preview

Go deeper on GIO Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GIO Therapeutics.

Explore the full profile